Pew

The Pew-Stewart Scholars for Cancer Research

Annual report prepared for
The Alexander and Margaret Stewart Trust
September 2025

Contents

Cover photo credit: The Pew Charitable Trusts

Introduction

On August 12, 2025, Pew announced the 12th class of the Pew-Stewart Scholars for Cancer Research: five early-career scientists who will pursue new avenues for diagnosing, preventing, and treating various types and stages of cancer. They join 58 Pew-Stewart scholars and alumni from 32 institutions who are driving advances within the field of cancer research.

Through the generous investment of the Alexander and Margaret Stewart Trust (Stewart), the Class of 2025 will explore a range of critical topics, including genetic determinants of leukemia and lymphomas, the role of dietary fats in promoting tumor growth and resistance, and how T cells and RNA may be used to develop precision immunotherapies.

Meanwhile, current scholars and alumni of the program continue to transform our understanding of the development and effective treatment of myriad cancers. Building on the foundational support from Stewart, they innovate with new technologies, explore novel approaches to long-standing challenges with intractable cancers, and develop insights into the building blocks and mechanisms of fatal forms of this disease. Former Pew-Stewart scholars strengthen the overall field: collaborating with current Pew-Stewart scholars and other fellow alumni, training and advising emerging researchers, and publishing peer-reviewed and influential findings.

This year, we recognized your impact over the past decade in a Trust Magazine article on the 40th anniversary of Pew's biomedical programs, and in a Winter 2025 article in *ROI at The Pew Charitable Trusts* depicting the evolution of our longstanding partnership.

We are pleased to share program highlights from the past year, which illustrate many ways the Pew-Stewart scholars community continues to shape cancer research. This report includes biographies and project descriptions for the newest class of Pew-Stewart Scholars, notable achievements and distinctions for Pew-Stewart scholars and alumni, and updated data on applicants and nominating institutions.

Class of 2025 Pew-Stewart Scholars

Iain Clark, Ph.D., University of California, Berkeley

Ryan Flynn, M.D., Ph.D., Boston Children's Hospital

Javier Garcia-Bermudez, Ph.D., Children's Medical Center Research Institute at UT Southwestern

Anna Nam, M.D., Weill Cornell Medicine

Bingfei Yu, Ph.D., University of Southern California

Pew-Stewart Scholars News and Updates

Members of the Pew-Stewart scholars community—current scholars, alumni, and advisory committee members alike—continue to be recognized for their excellence in cancer research. Here are some of their many honors, accolades, and achievements over the past year:

Pew-Stewart National Advisory Committee

Susan Kaech of the Salk Institute for Biological Studies was elected to the National Academy of Sciences—one of the highest honors accorded to a scientist in the United States. She is one of 120 new members and 24 international members elected this year, in recognition of her achievements in transforming the fields of immunology and cancer biology and inspiring new approaches to cancer immunotherapy.

Howard Chang, a professor at Stanford University, accepted the prestigious position of senior vice president, Global Research, and chief scientific officer at Amgen. There, Dr. Chang will lead all aspects of discovery research. Two members of the 2025 Pew-Stewart cohort, Ryan Flynn and Bingfei Yu, completed their training under Dr. Chang, who cycled off the National Advisory Committee in April 2025.

Class of 2024

Justin Eyquem of the University of California, San Francisco was one of a team of six researchers who received the 2025 Endeavor Award in Partnership with the Torrey Coast Foundation. The Endeavor Awards are designed to help break down silos that limit collaboration and innovation, providing multidisciplinary teams the freedom and flexibility to explore complex challenges through diverse lenses. With the three-year, $3 million award, Dr. Eyquem and his collaborators will work to develop enhanced CAR T-cell therapies for gastrointestinal (GI) cancers. These cancers are among the most lethal, with extremely low survival rates in the advanced stages. This research team, comprising experts in oncology, cancer immunology, genetic engineering, synthetic biology, and functional genomics, will apply cutting-edge approaches from each of their disciplines to help identify novel targets, enabling recent therapeutic advancements to be applied to specific gastric cancers that are notoriously difficult to treat. Their findings could lead to more effective immunotherapies, potentially revolutionizing treatments and improving outcomes for patients with gastric cancer.

Yogesh Goyal, Northwestern University's first Pew-Stewart scholar, utilized the computational Pew-Stewart toolkit that he designed to investigate vascular development, specifically the aorta, and how the body orchestrates cellular communication by building an internal biological blueprint and signals to various cellular systems to determine the

right size for all cells to come together to form organs and structures. Dr. Goyal's computational expertise in mathematical modeling demonstrates the interdisciplinary nature of his work and the value of employing cutting-edge technology for biological discovery and a deeper understanding of cancer development. His work will improve approaches to cancer prevention and treatment modalities.

Class of 2023

Liron Bar-Peled of Massachusetts General and Harvard Medical School received the Mark Foundation 2025 Emerging Leader Award. This award empowers outstanding early-career investigators to take on innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer patients. His project focuses on oncogenic protein fusions, which arise from the abnormal joining of two genes and drive tumor growth in a significant portion of cancers. While some drugs have been developed to target specific fusions, they often focus on a limited number of proteins and face challenges with drug resistance. Dr. Bar-Peled's project offers a promising new strategy for cancer therapy: A new class of small-molecule therapeutics called molecular staples will be designed to bind and disrupt protein interactions within oncogenic fusions, halting their pathogenic activities.

Dr. Bel-Peled also built on his Pew-Stewart work this year, publishing an article in Nature that investigated proteins that detect and neutralize reactive oxygen species (ROS). In ovarian cancers, certain chemotherapies produce ROS to interfere with how cancer cells generate energy. However, these aggressive cancers can quickly adapt and become resistant to such treatments. In the article, Dr. Bar-Peled demonstrates that specific proteins that detect ROS and their features are key cellular communicators in cancer. His work exhibits that lower-than-normal levels of these proteins can indicate therapeutic resistance. This information may be used to alert clinicians to resistance and identify alternative therapeutic options when patients no longer respond to chemotherapy.

Luisa Escobar-Hoyos of the Yale School of Medicine received the 2025 Pershing Square Sohn Cancer Prize, which is awarded annually to cancer research scientists and physician-scientists based in the greater New York City area. Dr. Escobar-Hoyos will contribute to the region's growing biomedical research hub by developing a novel pancreatic cancer vaccine that harnesses the body's existing immunity to Streptococcus bacteria to target and destroy pancreatic tumors. Her prize-funded research will investigate the mechanism behind this immune response and evaluate the vaccine's effectiveness, potentially leading to a new therapeutic strategy against this deadly cancer. In addition to funding, she will have opportunities to present her work to scientific and business audiences to explore collaborations and help bridge the gap between academia and industry.

Class of 2022

Monther Abu-Remaileh of Stanford University and his collaborators shared their work in Cell Metabolism earlier this summer. This article builds upon his Pew-Stewart research on how the lysosome, an organelle, plays an essential role in breaking down cellular materials for KRAS-driven cancers, such as pancreatic and non-small cell lung cancers. Dr. Abu-Remaileh and colleagues have presented new biology in which exposure to cold temperatures signals to specialized cells in the liver to conserve and maintain energy by quickly shifting how they convert and break down lipids (fat molecules). Lysosomes play a key role in this process. These findings, which reveal novel insights into liver adaptation to environmental stressors, can pave the way for discovering new therapeutic interventions for lysosomal storage disorders and metabolic diseases.

Class of 2021

Ansuman Satpathy of Stanford University was also a 2025 recipient of the Mark Foundation Emerging Leader Award as one of five outstanding early-career scientists dedicated to revolutionizing cancer research through innovative projects. Dr. Satpathy will work to generate more effective cancer immunotherapies, which can be limited by dysfunctional T cell states, such as exhaustion. He aims to overcome this limitation by engineering novel, "synthetic" T cell states with enhanced anti-tumor activity, building on his novel approach to generating synthetic transcription factors (synTFs). Dr. Satpathy's efforts will provide the field with valuable new resources for identifying and characterizing T cell states that possess superior cancer-fighting abilities.

Liling Wan of the University of Pennsylvania also received a 2025 Pershing Square Sohn Cancer Prize, which empowers early-career investigators to pursue exciting research projects at a stage when traditional funding is lacking. Dr. Wan is investigating transcriptional condensates—membrane-less assemblies that concentrate transcriptional machinery at specific locations in the genome to regulate gene expression. Her project aims to uncover how cancer cells hijack these condensates to reshape 3D genome organization and control gene activity in ways that promote tumor development. Dr. Wan joins 77 scientists at 14 institutions in the greater New York area who have received this award over the past 12 years.

Class of 2020

Mara Sherman of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine is one of three Pew-Stewart Scholars to receive the prestigious Mark Foundation Emerging Leader Award in 2025. With this funding, Dr. Sherman will research pancreatic ductal adenocarcinoma (PDAC), an aggressive cancer with a dismal prognosis due in part to its

complex tumor microenvironment. She will explore the interplay between cancer cells and the surrounding stromal cells, focusing on the diverse roles of cancer-associated fibroblasts (CAFs)—key players in the tumor microenvironment that contribute to tumor growth, metastasis, and treatment resistance. By understanding the various types and functional roles of these CAFs, her study aims to identify new vulnerabilities that can be used in PDAC therapies.

Class of 2018

Kivanç Birsoy of Rockefeller University collaborated with 2021 Pew-Stewart scholar Dr. Abu-Remaileh—whose groundbreaking work is featured above—on an invited review in Nature Metabolism. In this review article, Drs. Birsoy and Abu-Remaileh discussed how micronutrients, specifically choline, are essential for health and biological function. This intersection is a synergistic example of how the Pew-Stewart program can lead to shared research interests and collaborations.

Program Highlights

Pew Biomedical Scholars Program annual meeting

This year, the Pew Biomedical Scholars Program marks its 40th anniversary, a milestone we commemorated at our annual meeting in Bermuda from March 28 to April 2, 2025. We invited select alumni of the program to join the celebration, including the Pew-Stewart classes of 2021-2024, the advisory committee, and Stewart trustees. We were pleased to have four members of the Pew-Stewart advisory committee join us. Pew CEO Sue Urahn, executive vice president Michael Caudell-Feagan, and senior vice president for Philadelphia and Scientific Advancement Donna Frisby-Greenwood were also in attendance. Pew and the Stewart trustees celebrated Howard Chang's final year as a committee member, and the advisory committee enjoyed lunch with Sue, Michael, Donna, and the Stewart trustees. As always, the annual meeting was a wonderful experience for all three Pew Biomedical programs to network and grow their community.

Other convenings

In April, Donna Dang, principal associate of the Pew Biomedical Scholars Program, attended the American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois. Dr. Dang attended many scientific sessions focused on the leading edge of cancer research, featuring members of the Pew biomedical community as chairs or invited speakers. This included current Pew-Stewart scholars, alumni, and members of the national advisory committee. Dr. Dang attended sessions and talks given by Navdeep Chandel (advisor), Min Yu (2015), Ömer Yilmaz (2016), Kivanç Birsoy (2018), Sabrina

Spranger (2019), Liron Bar-Peled (2023), and Elvin Wagenblast (2023). Additionally, many past and current Pew-Stewart scholars had trainees and collaborators presenting their projects at AACR.

Summer interns pilot program

Pew and Stewart partnered with summer internship programs in universities across the country for a pilot program to bolster the scientific pipeline for undergraduates interested in pursuing a career in cancer research. With Stewart's support, five undergraduate summer interns engaged in cancer research alongside Pew-Stewart scholars, including Shasha Chong (2022) at the California Institute of Technology, Francine Garrett-Bakelman (2021) at the University of Virginia, Anders Hansen (2021) at the Massachusetts Institute of Technology, Alexander Huang (2022) at the University of Pennsylvania, and Humsa Venkatesh (2024) at Harvard University.

Class of 2026 selection process

The application review process for the 2026 Pew-Stewart Scholar awards launched in September 2025, when Pew invited 95 cancer research centers and institutions to nominate a candidate. Overall, 80 institutions nominated candidates for the 2026 award, and the program has received 76 applications.

Pew and the Pew-Stewart National Advisory Committee (**Appendix II**) began formal reviews of these applications in September 2025. A final selection meeting will take place in person during the annual Pew biomedical programs meeting, held in Palm Springs, California, in March 2026.

Program Trends and Updates

Since 2015, Pew and Stewart have partnered to support 63 outstanding early-career investigators. Below are details about how the program has evolved, as well as aggregate data about the scholars and their institutions.

Nomination process

With the addition of Stony Brook University to the 2026 nominating pool, there are now 95 institutions on the nominating list for the Pew-Stewart Scholars program. The list, which was initially based on cancer centers designated by the National Cancer Institute (NCI), now includes subsequent additions to NCI's designees as well as high-caliber institutions whose requests to be considered have been approved by our advisory committee. In total, the number of nominating institutions for this program has grown 34% since 2015.

The full list of nominating institutions for the 2026 Pew-Stewart Scholars awards is available in **Appendix III**.

Awarded Institutions

Pew-Stewart scholars and alumni come from 32 institutions, as shown in the graph in **Appendix IV**. The highest number of awardees have come from Massachusetts Institute of Technology and University of California, Berkeley (five each); Caltech and University of California, San Francisco (four each); and New York University, Stanford University, University of Pennsylvania, and Yale University (three each).

Research focus

The Pew-Stewart Scholars program often reflects emerging trends within the field of cancer research through the various scientific approaches our investigators take.

The 2025 class of Pew-Stewart Scholars promises to be the most balanced in terms of its approaches, with each of our scholars focusing on a different research field. This year, their work covers metabolism, genomics, immunology, cancer cell biology, and biomedical engineering.

This is a strong representation of the current research interests at the leading edge of cancer discovery. Currently, the field is observing increased activity surrounding cancer metabolism, gene regulation, and cancer immunology, with a particular emphasis on immunotherapy development. The 2025 class is an indicator that the Pew-Stewart Scholars program continues to identify talented investigators who are emerging leaders in cancer research.

A chart depicting funded research fields over time is attached as **Appendix VI.**

Cancer research in the Pew-Scholars Program

The Pew Scholars program continues to stand alongside the Pew-Stewart Scholars program in its support of cancer research. For each year from 2007 to 2025, between one and three Pew scholars have included cancer within their research program—40 altogether. Since 2015, the Pew Scholars program has supported 18 researchers in their pursuit of cancer-focused research.

Appendix I: 2025 Pew-Stewart Scholars

Iain Clark, Ph.D.
University of California, Berkeley

Mixed phenotype acute leukemia (MPAL) is one of the most lethal and poorly understood forms of acute leukemia. Defined by co-expression of lymphoid and myeloid markers, MPAL lacks clear genetic subtypes. A key unanswered question in MPAL biology is how genetic mutations—many of which are shared with more treatable leukemias—lead to lineage ambiguity and treatment resistance. Recent work suggests that MPAL cells converge on a stem-like transcriptional program that correlates with patient survival. However, existing technologies cannot track how mutational evolution drives leukemic cells into this stem-like, therapy-refractory state. To overcome this, Clark is developing a single-cell platform that simultaneously profiles genomic and transcriptomic information from individual cells. He will apply this technology to MPAL patient samples collected during treatment, remission, and relapse to reconstruct how sequential mutations shape transcriptional programs, drive clonal evolution, and influence clinical outcomes.

Ryan Flynn, M.D.
Boston Children's Hospital

The Flynn lab investigates how molecules, such as RNAs, influence cellular processes in the context of human disease. Flynn's recent work established that RNAs and RNA-binding proteins (RBPs) are present on the surface of many cell types, with some of these cell-surface RBPs specifically associated with tumors. For example, the RBP NPM1 is selectively present on the surface of acute myeloid leukemia (AML) cells. Because effective cell therapy for cancer requires the identification of cell-surface proteins unique to malignant cells, Flynn hypothesizes that cell-surface RBPs, such as NPM1, may be useful as therapeutic targets. To explore this possibility, he will establish the scope of cell-surface NPM1 expression on solid and liquid tumors to better understand its clinical implications. He will also define the mechanistic dynamics of cell-surface NPM1. Finally, he will examine various methods for targeting cell-surface NPM1 to achieve an efficacious treatment for AML. This work explores the new territory of cell-surface RNA biology and its potential to yield targets for cancer-selective therapeutic approaches.

Javier Garcia-Bermudez, Ph.D.
Children's Medical Center Research Institute at UT Southwestern

Many cancers enhance both lipid synthesis and uptake to support their progression, but the complexity and diversity of lipids have hindered a complete understanding of their roles in cancer progression. Lipoproteins, the primary carriers of lipids in the blood, are avidly taken up by tumors; however, how their complex lipid cargo influences cancer progression remains unclear. This is especially relevant given that lipoprotein levels are often elevated in cancer patients due to common comorbidities such as obesity and diabetes. The Garcia-Bermudez lab investigates how tumor-acquired exogenous lipids, primarily those derived from lipoproteins, promote cancer aggressiveness. He will combine modulation of lipoprotein uptake in tumors, genetic manipulation of circulating lipoprotein levels in mouse models, and in vivo lipid-focused genetic screens to uncover lipid-driven mechanisms that support tumor growth, metastasis, and therapy resistance. His goal is to define how cancer cells exploit host lipid pools and identify metabolic vulnerabilities that may be targeted to improve patient outcomes.

Anna Nam, M.D.
Weill Cornell Medicine

The Nam lab focuses on factors that influence the relationship between genotype and phenotype in blood cancers. Blood cancers are caused by genetic mutations, which can result in various phenotypes and patient outcomes. Nam will investigate the elements underlying the phenotypic differences between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma. She has found that some HL cells feature unique characteristics associated with changes in the tumor microenvironment (TME), including elevated inflammatory signaling and neural reprogramming. Now, she will investigate these characteristics and their effects on cell function using new single-cell multi-omics methods that measure genetic and nongenetic contributors to HL cell diversification. She will determine how changes in cell characteristics are regulated at the transcriptional and epigenetic levels, identify interactions between lymphoma cells and the TME that promote cancer fitness, and decipher the functional consequences of these changes in lymphoma via mechanistic studies. These studies may lead to novel therapeutic approaches for HL.

Bingfei Yu, Ph.D.
University of Southern California

The Yu lab studies how immune cells, especially T cells, recognize and target threats to develop precision immunotherapies for cancer and other diseases. T cells identify threats through antigens presented on human leukocyte antigen (HLA) proteins, which help distinguish the body's own proteins from those produced by pathogen or cancer cells. However, HLA proteins vary extensively from person to person, posing a significant challenge: Current T cell-based immunotherapies are primarily designed for one HLA type and are ineffective for others, resulting in disparities in treatment access and efficacy. To address this, Yu will decipher how T cells recognize HLA antigens across diverse populations, facilitating the development of broadly effective cancer immunotherapy. First, she will develop a novel antigen discovery platform to identify cancer antigens that are effective across HLA types found in more than 90% of the global population. Then, Yu will determine how to program T cells to recognize these antigens. This work can make strides toward developing universal cancer immunotherapies, with significant potential to improve global health outcomes for cancer.

Previous Classes of Pew-Stewart Scholars

Class of 2024 Pew-Stewart Scholars

Aparna Bhaduri, Ph.D., University of California, Los Angeles
Justin Eyquem, Ph.D., University of California, San Francisco
Yogesh Goyal, Ph.D., Northwestern University
Shiri Gur-Cohen, Ph.D., University of California, San Diego
Humsa Venkatesh, Ph.D., Brigham and Women's Hospital, Harvard Medical School

Class of 2023 Pew-Stewart Scholars

Liron Bar-Peled, Ph.D., Massachusetts General Hospital
Luisa Escobar-Hoyos, M.Sc., Ph.D., Yale University
Gerta Hoxhaj, Ph.D., University of Texas Southwestern Medical Center
Elvin Wagenblast, Ph.D., Icahn School of Medicine at Mount Sinai
Ziyang Zhang, Ph.D., University of California, Berkeley

Class of 2022 Pew-Stewart Scholars

Monther Abu-Remaileh, Ph.D., Stanford University

Alexander Bick, M.D., Ph.D., Vanderbilt University Medical Center
Shasha Chong, Ph.D., California Institute of Technology
Alexander Huang, M.D., University of Pennsylvania
Chengcheng Jin, Ph.D., University of Pennsylvania
Christina Towers, Ph.D., The Salk Institute for Biological Studies

Class of 2021 Pew-Stewart Scholars

Francine Garrett-Bakelman, M.D., Ph.D., University of Virginia
Anders Sejr Hansen, Ph.D., Massachusetts Institute of Technology
Ansuman Satpathy, M.D., Ph.D., Stanford University
David Van Valen, M.D., Ph.D., California Institute of Technology
Liling Wan, Ph.D., University of Pennsylvania

Class of 2020 Pew-Stewart Scholars

Shruti Naik, Ph.D., New York University Langone Health
Srinivas Ramachandran, Ph.D., University of Colorado School of Medicine
Mara Sherman, Ph.D., Memorial Sloan Kettering Cancer Center
Xuebing Wu, Ph.D., Columbia University
Jihye Yun, Ph.D., MD Anderson Cancer Center

Class of 2019 Pew-Stewart Scholars

Michel DuPage, Ph.D., University of California, Berkeley
Luke Gilbert, Ph.D., University of California, San Francisco
Diana Hargreaves, Ph.D., The Salk Institute for Biological Studies
Piro Lito, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Chao Lu, Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University
Stefani Spranger, Ph.D., Massachusetts Institute of Technology
Gabriel Victora, Ph.D., The Rockefeller University

Class of 2018 Pew-Stewart Scholars

Michael Birnbaum, Ph.D., Massachusetts Institute of Technology
Kivanç Birsoy, Ph.D., The Rockefeller University
Aaron M. Ring, M.D., Ph.D., Fred Hutchinson Cancer Center
Alex K. Shalek, Ph.D., Massachusetts Institute of Technology
Rebecca M. Voorhees, Ph.D., California Institute of Technology

Class of 2017 Pew-Stewart Scholars

Daniel A. Bachovchin, Ph.D., Memorial Sloan Kettering Cancer Center
Nadya Dimitrova, Ph.D., Yale University

Charles Y. Lin, Ph.D., Kronos Bio, Inc.
Robert K. McGinty, M.D., Ph.D., University of North Carolina, Chapel Hill
Sabrina L. Spencer, Ph.D., University of Colorado, Boulder

Class of 2016 Pew-Stewart Scholars

Stephanie Dougan, Ph.D., Dana Farber Cancer Institute, Harvard University
Dirk Hockemeyer, Ph.D., University of California, Berkeley
Paul Northcott, Ph.D., St. Jude Children's Research Hospital
Richard L. Possemato, Ph.D., Perlmutter Cancer Center, NYU School of Medicine
Ömer H. Yilmaz, M.D., Ph.D., Koch Institute for Integrative Cancer Research at MIT

Class of 2015 Pew-Stewart Scholars

Trever Bivona, M.D., Ph.D., University of California, San Francisco
Adam de la Zerda, Ph.D., Stanford University
Mitchell Guttman, Ph.D., California Institute of Technology
Cigall Kadoch, Ph.D., Dana-Farber Cancer Institute and Harvard Medical School
Min Yu, M.D., Ph.D., University of Maryland Medical School

Class of 2014 Pew-Stewart Scholars

Arvin Dar, Ph.D., Icahn School of Medicine at Mt. Sinai
Shawn M. Douglas, Ph.D., University of California, San Francisco
Andrew J. Holland, Ph.D., Johns Hopkins University, School of Medicine
Agnel Sfeir, Ph.D., Memorial Sloan Kettering Cancer Center
Roberto Zoncu, Ph.D., University of California, Berkeley

APPENDIX II: The Pew-Stewart National Advisory Committee

This year, we welcomed Siavash Kurdistani to the national advisory committee, starting with the 2026 Pew-Stewart cycle. Dr. Kurdistani earned his medical degree at Harvard University and completed his specialty training in pathology. He brings expertise in epigenetics and comparative genomics, as well as both basic science and clinical perspectives, to the committee.

As of July 2025, the Pew-Stewart National Advisory Committee is:

Helen Piwnica-Worms, Ph.D. (Chair)
Professor of Experimental Radiation Oncology
MD Anderson Cancer Center

Navdeep S. Chandel, Ph.D.
David W. Cugell Professor of Medicine & Biochemistry and Molecular Genetics
Feinberg School of Medicine
Northwestern University

Susan Kaech, Ph.D.
Professor and Director Nomis Foundation Chair Nomis Center for Immunobiology and Microbial Pathogenesis
The Salk Institute for Biological Studies

Siavash Kurdistani, M.D.
Chair of Biological Chemistry
Professor of Pathology and Laboratory Medicine
University of California, Los Angeles

Sohail Tavazoie, M.D., Ph.D.
Leon Hess Professor, Meyer Laboratory of Systems Cancer Biology
Director, Black Family Metastasis Center
The Rockefeller University

APPENDIX III: 2026 Institutional Nominations

Institutions that nominated a candidate (80)

- Abramson Cancer Center, University of Pennsylvania
- Albert Einstein Cancer Center
- Alvin J. Siteman Cancer Center, Washington University School of Medicine and Barnes-Jewish Hospital
- Arizona Cancer Center, University of Arizona
- Boston University-Boston Medical Center Cancer Center
- Brown University
- Cancer Center at Illinois, University of Illinois at Urbana-Champaign
- Case Comprehensive Cancer Center, Case Western Reserve University
- Cedars-Sinai Medical Center
- Chao Family Comprehensive Cancer Center, University of California, Irvine
- City of Hope Comprehensive Cancer Center
- Cold Spring Harbor Laboratory Cancer Center
- Dan L. Duncan Cancer Center, Baylor College of Medicine
- Dana Farber/ Harvard Cancer Center, Harvard University
- David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology
- Duke Cancer Institute, Duke University Medical Center
- Fox Chase Cancer Center
- Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center
- Fred Hutchinson/University of Washington Cancer Consortium
- Georgetown Lombardi Comprehensive Cancer Center, Georgetown University
- Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center
- Herbert Irving Comprehensive Cancer Center, Columbia University
- Holden Comprehensive Cancer Center, University of Iowa
- Hollings Cancer Center, Medical University of South Carolina
- Huntsman Cancer Institute, University of Utah
- Indiana University Melvin and Bren Simon Cancer Center, Indiana University
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles
- Knight Cancer Institute, Oregon Health and Science University
- Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center
- Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore

- Markey Cancer Center, University of Kentucky
- Massey Cancer Center, Virginia Commonwealth University
- Mayo Clinic Cancer Center
- Mays Cancer Center, University of Texas Health San Antonio
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- National Cancer Institute
- Norris Cotton Cancer Center at Dartmouth, Dartmouth-Hitchcock Medical Center
- O'Neal Comprehensive Cancer Center at the University of Alabama
- Purdue University Center for Cancer Research, Purdue University
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
- Roswell Park Cancer Institute
- Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College
- Sanford Burnham Prebys Medical Discovery Institute
- Sidney Kimmel Comprehensive Cancer Center of the Johns Hopkins University School of Medicine
- Sidney Kimmel Cancer Center, Thomas Jefferson University
- St. Jude Children's Research Hospital
- Stanford Cancer Institute, Stanford University
- Stony Brook University
- The Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine
- The Cancer Institute of New Jersey, Rutgers University
- The Children's Hospital of Philadelphia
- The Jackson Laboratory Cancer Center
- The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- The University of Chicago Comprehensive Cancer Center
- The University of Kansas Cancer Center
- The University of Texas at Austin
- The University of Texas MD Anderson Cancer Center
- The Wistar Institute Cancer Center
- University of California, Berkeley
- University of California, Davis Comprehensive Cancer Center
- University of California, San Diego Moores Cancer Center

- University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
- University of California, Santa Cruz
- University of Colorado Cancer Center
- University of Florida Health Cancer Center
- University of Illinois Cancer Center, University of Illinois at Chicago
- University of Massachusetts Cancer Center
- University of Michigan Rogel Cancer Center
- University of New Mexico Cancer Center
- University of North Carolina Lineberger Comprehensive Cancer Center
- University of Virginia Cancer Center
- University of Wisconsin Carbone Cancer Center
- University of Southern California Norris Comprehensive Cancer Center
- Wake Forest Baptist Comprehensive Cancer Center
- Vanderbilt-Ingram Cancer Center
- Wilmot Cancer Institute, University of Rochester
- Winship Cancer Institute, Emory University
- Yale Cancer Center, Yale University School of Medicine

Institutions that did not nominate a candidate (15)

- Anderson Center for Cancer Research, The Rockefeller University
- California Institute of Technology
- Howard University Cancer Center, Howard University
- Masonic Cancer Center, University of Minnesota
- Penn State Cancer Institute, Pennsylvania State University
- Salk Institute Cancer Center
- Stephenson Cancer Center, University of Oklahoma
- Stowers Institute for Medical Research
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
- The University of Texas Medical Branch
- University of Hawaii Cancer Center
- University of Pittsburgh Medical Center Hillman Cancer Center
- University of Vermont Cancer Center
- Van Andel Research Institute
- Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences

APPENDIX IV: Awards by Academic Institution



APPENDIX V: Funded Research Fields Over Time

This chart represents the seven separate research fields that the 63 Pew-Stewart scholars have addressed. Since the program launched in 2014, most classes have consisted of five awardees, except for 2022 (six awardees) and 2019 (seven awardees).